Evidence suggests that adenosine modulates neuronal and cerebral vascular functions by interacting with specific receptors on brain cells and blood vessels. Adenosine and other nucleosides are also transported across the blood-brain barrier via a saturable, carrier mediated mechanism. Using direct ligand binding methods, we studied the two adenosine receptor sub types, Al and A2 and the nucleoside transporter moiety in human brain ' microvessels, pial vessels, choroid plexus, and cerebral cortex membranes. The following specific tritiated ligands were used: cyclohexyladenosine (CHA) for Al receptors; 5'-N-ethylcarboxamide adeno sine (NECA) for A2 receptors; nitrobenzylthioinosine (NBMPR) and dipyridamole (DPY) for nucleoside trans porters. We find that cerebral microvessels, pial vessels, and choroid plexus have few, if any, Al receptors, in con tradistinction to cerebral membranes, which have a 1O-20-fold higher density of Al receptor sites. Specific
It is generally accepted that adenosine modulates central nervous system functions via its interaction with adenosine I (AI) and adenosine2 (A2) receptors located on cell membranes (Phillis and Wu, 198 1; Daly et aI., 1983) . Al receptor agonists inhibit cy clic adenosine monophosphate formation, whereas A2 receptor stimulation increases adenylate cyclase activity and cAMP synthesis (Daly et aI., 1981) . Marked changes in extracellular adenosine concen trations were described in a variety of conditions high-affinity NECA binding to A2 receptors in cerebral microvessels, pial vessels, and choroid plexus was satu rable and was equivalent to that of cerebral cortical membranes. The Bmax and Kd of the high-affinity NECA binding to vessel preparations were � 1.3 pmol/mg pro tein and �250 nM, respectively, which is similar to our previous findings in the rat and pig. NBMPR and DPY binding were also saturable and were consistent with a single class of high-affinity binding sites. The density of nucleoside transporters was �four-fold higher in cerebral microvessels than in cerebral cortex, pial vessels, and choroid plexus. These results suggest that human cere bral microvessels have A2 but not Al receptors and are particularly enriched with the adenosine transporter moiety. Key Words: Adenosine receptors-Blood-brain barrier-capillary endothelium-Cerebral blood vessels -Nucleoside transporter.
that perturb brain functions, such as ischemia, hyp oxia, hypoglycemia, and status epilepticus. Also, there is evidence suggesting that adenosine and its analogs dilate cerebral blood vessels and increase brain perfusion (Winn et aI., 1981; Berne et al., 1983) . On the other hand, it is also known that adenosine and other nucleosides (guanosine, ino sine, and uridine) traverse cell membranes, in cluding the blood-brain barrier (BBB), by a car rier-mediated, saturable, nonconcentrative, and non-energy-requiring facilitated diffusion mecha nism (Cornford and Oldendorf, 1975; Young and Jarvis, 1983) .
We have previously demonstrated by specific li gand binding methods the existence of A2 receptors in rat and pig cerebral microvessels, but have found paucity of Al receptors in these vessels (Kalaria and Harik, 1986a) . We likewise demonstrated a five fold higher maximal binding (Bmax) of the nu cleoside transporter ligand in rat and pig brain mi-crovessels than in membranes of the cerebral cortex (Kalaria and Harik, 1986b) . In this article, we extend our experiments to the identification and quantitation of adenosine receptors and the nucleo side transporter in human cerebral cortex, brain microvessels (which constitute the BBB), pial blood vessels (which include resistance vessels that control brain blood flow) and the choroid plexus.
We investigated adenosine receptors using [3Hlcyclohexyladenosine (CHA) as a ligand for the Al receptor and [3Hl5'-N-ethylcarboxamide adeno sine (NECA) as a ligand for the A2 receptor. For the adenosine transporter, we used two ligands [3Hlnitrobenzylthioinosine (NBMPR) and dipyrid amole (DPY)-both of which are potent competi tive inhibitors of nucleoside transport in a variety of mammalian tissues (Paterson et al. , 198 1; Young and Jarvis, 1983) . DPY was used because of recent evidence indicating that it inhibits, in some tissues, an NBMPR-insensitive nucleoside transport com ponent (Belt, 1983; Davies and Hambley, 1986; Jarvis, 1986) 
MATERIALS AND METHODS

Preparation of tissues
Human brains were sampled at autopsy from five sub jects (four men and one woman) who died as a result of motor vehicle accidents. The subjects' ages ranged from 29 to 58 years. The time between death and brain sam pling ranged from 3 to 12 h. There was no evidence of brain disease in any subject. A sample of the frontal cere bral cortex (Brodmann's area 8 or 9) was used as a repre sentative of the cerebral cortex. The choroid plexus was obtained from the lateral ventricles. P2 fractions of these tissues were prepared by homogenization in 0.3 M su crose solution, containing 5 mM sodium phosphate buffer, pH 7.0. The homogenates were centrifuged at 1,000 g for 10 min, and the supernatants were recentri fuged at 40,000 g for 20 min. The pellets were washed twice in 50 mM Tr is buffer, pH 7.4, and were stored at -80°C until used. All procedures were performed at 0-4°C.
About 200 g of the frontal cortical mantle of the same brains were dissected free of meninges and used for mi crovessel isolation, as described previously (Harik et a!. , 1985) . Each microvessel preparation was obtained from the cortex of one subject. Microvessel purity was checked by microscopy and by biochemical assays of en richment with ,),-glutamyl transpeptidase, alkaline phos phate, and angiotensin-converting enzyme, markers of endothelial cell membranes ( Table 1 ). The rest of the mi crovessels were stored at -80°C until used. Pial vessels were prepared by stripping the pia-arachnoid off the un derlying cortex and cleaning it from any attached brain tissue. The pia-arachnoid was then homogenized in 0.3 M sucrose solution containing 5 mM sodium phosphate buffer, pH 7.0, in a Brinkmann polytron. The homoge nates were centrifuged at 40,000 g for 20 min, and the pellets were washed twice in 50 mM Tr is buffer, pH 7.4, and stored at -80°C until used. All tissue preparative procedures took place at 0-4°C unless otherwise stated. Particulate fractions of cerebral microvessels and pial vessels and the P2 fractions of the choroid plexus and ce rebral cortex were prepared for binding assays by poly tron rehomogenization and mixing in 50 mM Tr is buffer to obtain a tissue concentration of 1-2 mg tissue protein/m!. All tissues used for receptor studies were incubated with adenosine deaminase (5 U/ml) for 30 min at 22°C to me tabolize endogenous adenosine.
CHA binding studies were washed 3 times with 4 ml of cold buffer and assayed for their 3H content by liquid scintillation counting at �45% efficiency. Specific binding was defined as the dif ference between total binding and nonspecific binding in the presence of 100 fLM unlabeled 2-CA. Nonspecific
[3H]CHA binding to cerebral cortical preparations did not exceed 20% of total binding at [3H]CHA concentrations as high as 15 nM. In a typical experiment, total and non specific binding to 88 fLg of cerebral cortex P2 protein were 1,144 and 200 dpm, respectively, at 6 nM [3H]CHA.
NECA binding studies A2 receptors were studied by [3H]NECA binding. As NECA binds to both Al and A2 receptors (Yeung and Green, 1984; Bruns et a!. , 1986) , it was imperative that Al receptors be occupied to prevent [3H]NECA from inter acting with them. To achieve this, 50 nM of cyclopentyla denosine (CPA) was added to the incubation medium (Bruns et aI. , 1986) . PH]NECA binding was performed by incubating about 100 fLg tissue protein with varying concentrations of PH]NECA (specific activity 21 Ci/ mmol; New England Nuclear) at 22°C for 30 min. Binding was terminated by dilution with ice-cold buffer and rapid filtration under reduced pressure through Whatman GF/B filters. The washing-filtration step did not exceed 15 s.
The radioactivity retained by the filters after 3 washes with 4 ml of buffer was assayed by liquid scintillation counting at �45% efficiency. Nonspecific binding was R. N. KALARIA AND S. 1. HARIK estimated in parallel incubations containing unlabeled NECA or 2-CA, both at a concentration of 250 fLM. Spe cific binding was calculated by subtracting nonspecific binding from total binding. In a typical experiment where 2-CA was used to define nonspecific binding, total and nonspecific binding to 91 fLg cerebral microvessel protein were 2,184 and 735 dpm, respectively, at 100 nM PH]NECA.
NBMPR binding
[3H]NBMPR binding was performed at 22°C for 30 min. The incubation volume (0.2 m!) contained about 100 fLg tissue protein, varying concentrations of [3H]N BMPR (specific activity 39 Ci/mmol), with and without 20 fLM unlabeled nitrobenzylthioguanosine. Binding was termi nated by dilution with I ml of ice-cold Tr is buffer and rapid filtration under reduced pressure on Whatman GF/B filters. The filters were washed 3 times with 4 ml of buffer and were assayed for their 3H content by liquid scintillation counting at �45% efficiency. Specific binding was defined as the difference between total binding and nonspecific binding in the presence of 20 fLM nitrobenzylthioguanosine. In a typical experiment, total and nonspecific binding to 91 fLg cerebral microvessel protein were 1,456 and 162 dpm, respectively, at I nM [3H]NBMPR.
DPY binding
Given recent evidence indicating the existence of NBMPR-insensitive nucleoside transport (Belt, 
Analysis of data
The dissociation constants of binding (Kd) and maximal binding capacities (Bmaxl were calculated by the method of Scatchard (1949) , using the LIGAND program (Munson and Rodbard, 1980) .
RESULTS
Cerebral microvessel preparations examined by differential interference contrast microscopy con sisted of segments of capillaries, arterioles, and venules that ranged from 4 to 30 f1m in diameter, with the vast majority being < 10 f1m. Microvessels larger that 15 f1m often had smooth muscles in their walls, identified by their striations. Gross estimates of the relative contribution of vessels with smooth muscles by microscopic examination was -15%. Figure 1 shows representative photomicrographs of microvessels which, despite the fact that they were obtained several hours postmortem, did not differ in their gross morphology from those prepared from experimental animals in which microvessel isolation was started quickly after decapitation and brain removal. The purity of microvessels was also assessed biochemically by measuring the activity of ),-glutamyl transpeptidase, alkaline phosphatase, and angiotensin-converting enzyme, all of which were enriched by -25-fold in particulate fractions of microvessels over their activity in cerebral cortex (Table 1) . The pu rity of microvessels was consistent with previous reports from our laboratory, with contamination by neuronal and glial elements estimated at <5% (Harik et aI., 1981 (Harik et aI., , 1985 .
Specific [3H]CHA binding to Al receptors of human cerebral cortex was saturable. An example of the saturation isotherm is presented in Fig. 2 . Scatchard plots revealed a single class of binding sites (Fig. 2, inset) . However, specific binding of [3H]CHA to human cerebral microvessels, pial vessels, and choroid plexus was low, ranging be tween 5 and 9% of the Bmax in the frontal cerebral cortex (Table 2, Fig. 2) . These results indicate that cerebral microvessels, pial vessels, and choroid plexus preparations have a paucity of Al receptors when compared to cerebral cortex.
Specific [3H]NECA binding to particulate frac tions of cerebral microvessels and pial vessels and to P2 fractions of choroid plexus and cerebral cortex was saturable when either unlabeled NECA, 2-CA or L-phenylisopropyladenosine (L-PIA) were used to define nonspecific binding (Fig. 3) . When unlabeled NECA was used to define nonspecific binding, Scatchard analysis of specific [3H]NECA binding to these preparations gave curvilinear plots (Fig. 3, inset) . Analysis of these plots using the LI GAND curve-fitting program (Munson and Rod bard, 1980) indicated that the best fit for the data was a two-site model, with high-affinity and low-af finity sites, as described before for rat and pig prep arations (Kalaria and Harik, 1986a) . Different re- 
The values represent the means of 3-4 experiments ± SEM. suits were obtained when 250 JJ.M 2-CA or L-PIA were used to define nonspecific binding (Fig. 3,  inset) . The Scatchard plot now became linear, indi cating one class of binding sites, with the Kd ranging between 100 and 500 nM for all prepara tions. This is consistent with our previous work (Kalaria and Harik, 1986a) and that of others (Yeung and Green, 1984; Bruns et aI., 1986) , indi cating that 2-CA and other potent adenosine ago nists, such as L-PIA can be used to mask "nonre ceptor" or low-affinity NECA binding sites that ap pear to be ubiquitous in the brain (Daly et aI., 1983) . We concentrated on this high-affinity
[3H]NECA binding site and found that the Bmax re sults were comparable in cerebral microvessels, pial vessels, choroid plexus, and cerebral cortex (Table 3) .
[3H]NBMPR binding to particulate fractions of cerebral microvessels and pial vessels and to the P2 fractions of choroid plexus and cerebral cortex was also saturable. class of binding sites (Fig. 4, inset) . The Kd values were all < 1 nM, indicating high-affinity binding ( Given recent evidence indicating that NBMPR insensitive nucleoside transport may exist (Belt, 1983; Davies and Hambley, 1986; Jarvis, 1986) , we assessed the nucleoside transporter of all prepara tions using DPY as another ligand (Marangos et aI., 1985) . Specific binding of [3H]DPY to all of these preparations was higher than the binding obtained with [3H]NBMPR (Figs. 4 and 5) . The high-affinity binding of [3H]DPY to human cerebral micro vessels had a Bmax of 788 ± 280 fmol/mg protein and a Kd of 3.5 ± 1.3 nM (mean ± SEM, n = 4).
The corresponding values for human cerebral cortex P2 preparations were 292 ± 78 fmol/mg pro tein and 3. transporter, cerebral microvessels were 3-4-fold higher in their Bmax than the P2 fractions of the cere bral cortex.
Characterization of the [3H]NBMPR binding sites of human cerebral microvessels by covalent photolabeling, followed by SD S-PAGE analyses, indicated a distinct peak of radiolabeled protein(s) with an apparent molecular weight of �58,000. This peak was abolished when photolabeling was at tempted in the presence of excess unlabeled NBMPR or DPY (Fig. 6 ). This is consistent with our previous findings in cerebral micro vessels of the rat and pig (Kalaria and Harik, 1986b) .
DISCUSSION
The results on adenosine receptors in the human brain, its blood vessels, and choroid plexus confirm our previous results in the rat and pig (Kalaria and Harik, 1986a ). Now we have extended our studies The values represent the means of 3-5 experiments ± SEM. Table 3 .
to larger pial "resistance" blood vessels that have an important role in regulating cerebral blood flow. Microvessels are mostly capillaries, which are of prime importance in BBB transport functions, but are considered less important in blood flow control. We do not believe that our ligand binding results were much affected by the relatively long delay be tween death of the subjects and tissue acquisition for the following reasons: first, our present results in human tissues are similar to our prior findings in rat and pig preparations where postmortem delay was minimal (Kalaria and Harik, 1986a , b) . Second, we were unable to obtain any meaningful correlations between the binding results on one hand and the postmortem delay, which ranged from 3 to 12 h in the 5 subjects, on the other hand. Although CHA, the Al receptor ligand, bound to cortical membranes, there was little binding to ce rebral microvessels, pial vessels, or choroid plexus. On the other hand, we found that all these prepara tions are well endowed with A z receptor binding sites. These receptors are similar to those reported before in human platelets (Huttemann et aI., 1984) and rat brain microvessels and pia-arachnoid (P almer and Ghai, 1982) , although they exhibit lower affinity to adenosine analogs compared to those in rat striatum (Yeung and Green, 1984; Bruns et aI., 1986) . Whether or not the high-affinity binding sites for [3H]NECA that we refer to are the same as those designated as A2a subtype by Bruns et a!. (1986) and Daly et a!. (1983) is not clear. How ever, the vascular tissues we studied show A z re ceptor characteristics, as evident from studies on adenylate cyclase stimulation where the order of potency of adenosine agonists was NECA :? 2-CA » CHA > CPA (results not shown). It was pre viously shown that stimulation of these A2 re ceptors increases the activity of adenylate cyclase in microvessels obtained from rats (Huang and Drummond, 1979; Palmer and Ghai, 1982; Schutz et a!., 1982; Huang and Rorstad, 1983) , guinea pigs (Shimizu, 1983) , and rabbits (Y ing-Ou and Fred holm, 1985) . Similarly, Edvinsson and Fredholm (1983) showed cAMP accumulation in cat pial vessels with the same order of potency: NECA > 2-CA> L-PIA > CHA.
Although the exact physiological significance of A2 receptor stimulation in brain blood vessels is not fully understood, it is thought that increased cAMP synthesis by brain capillaries, which constitute the BBB, may alter BBB transport of a variety of micro-and macromolecules. In larger vessels that have smooth muscle, such as pial vessels, A2 re ceptor stimulation and the resultant increased cAMP generation most likely cause muscle relax-R. N. KALAR1A AND S. 1. HAR1K ation and decreased cerebrovascular resistance. This assumes the existence of A2 receptors on smooth muscle membranes of larger brain vessels. Adenosine and its analogs increase the caliber of pial arterioles and decrease vascular resistance (Winn et al., 1981) . The effects of A2 receptor ago nists on the functions of the choroid plexus are un known. I3-Adenergic agonists also stimulate cAMP generation. If l3-adenergic receptors mediate the ef fect of norepinephrine to decrease cerebral spinal fluid (CSF) formation by the choroid plexus, then it may be assumed that A2 receptor stimulation would yield similar action.
The nucleoside transporter performs entirely dif ferent functions than adenosine receptors. The nu cleoside transporter allows adenosine and other nu cleo sides (such as guanosine, inosine, and uridine), which are water soluble, to traverse biological membranes, including BBB. These nucleosides are not only precursors of important brain constituents, such as nucleic acids and nucleotides, but one of them, adenosine, is considered to be a neuromodu lator (Snyder, 1985) . As the brain has limited ca pacity for de novo synthesis of nucleosides, it has to rely on external sources for its supply (Pritchard et al., 1975) . The present results on NBMPR and DPY binding to the nucleoside transporter are con-J Cereb Blood Flow Metab, Vol. 8, No. 1, 1988 sistent with our previous findings in rat and pig, showing enrichment in brain microvessels (Kalaria and Harik, 1986h) . Pial vessels that are not pri marily concerned with transport have a low density of nucleoside transporters. The human choroid plexus appears different from that of pig in that is has lower density of nucleoside transporters.
We have questioned before the functional signifi cance of the high density of nucleoside transporters in brain capillaries, which can transport adenosine from blood-to-brain. Indeed, the relatively high permeability of the BBB to adenosine (Cornford and Oldendorf, 1975; LaManna et at., unpublished observations) is consistent with the high density of nucleoside transporters that we report here and in a previous study (Kalaria and Harik, 1986h) . We be lieve that adenosine taken up by brain capillary en dothelium is quickly metabolized in endothelial cells (Pearson and Gordon, 1985) . We previously reported that brain microvessels have considerable activities of adenosine deaminase, adenosine ki nase, S-adenosyl homocysteine hydrolase, and 5' nucleotidase, enzymes that are capable of metabo lizing adenosine and that presumably constitue a "biochemical BBB" by preventing the free trans port of adensosine from blood-to-brain (H arik and . Moreover, in view of the bidirec tionality of the transport process, it is possible that the prime function of the BBB nucleoside trans porter is the rapid removal of adenosine from the brain extracellular space after its massive release during certain pathophysiological conditions, such or absence (closed circles) of 10 fJ-M unlabeled DPY and were exposed to ultraviolet light at 4°C for 1 min. Samples were then analyzed by SDS-PAGE. Arrows with numbers in dicate positions of the molecular weight standards (x 103) from the same slab gel. The gel was sliced at 2-mm intervals, and the radioactive contents of these slices were extracted and counted. as brain hypoxia, ischemia, hypoglycemia, and status epilepticus (Berne et al. , 1983) . Prevention of such removal by nucleoside transport inhibitors such as DPY will potentiate the effects of adeno sine at its receptors in neuronal, glial, and vessel membranes (Berne et al. , 1983; Phillis et al., 1984) .
